Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRD4-mediated repression of p53 is a target for combination therapy in AML

11 Jan 2021

Abstract excerpt

Acute myeloid leukemia (AML) is a typically lethal molecularly heterogeneous disease, with few broad-spectrum therapeutic targets. Unusually, most AML retain wild-type TP53, encoding the pro-apoptotic tumor suppressor p53. MDM2 inhibitors (MDM2i), which activate wild-type p53, and BET inhibitors (BETi), targeting the BET-family co-activator BRD4, both show encouraging pre-clinical activity, but limited clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33431824
DOI: 10.1038/s41467-020-20378-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRD4-mediated repression of p53 is a target for combination therapy in AMLPMID 33431824Read ↗

BRD4-mediated repression of p53 is a target for combination therapy in AMLSemantic proximity Read ↗

MDM2 Antagonists and p53-Targeting Therapies in Cancer: Clinical Applications, Adverse Effects, and Resistance MechanismsSemantic proximity Read ↗

Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)Semantic proximity Read ↗

The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies.Semantic proximity Read ↗

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitorSemantic proximity Read ↗

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitorSemantic proximity Read ↗

A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia CellsSemantic proximity Read ↗

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic MalignanciesSemantic proximity Read ↗

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patientsSemantic proximity Read ↗

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.Semantic proximity Read ↗

BET inhibitors synergize with anti-PD1 by rescuing TCF1 <sup>+</sup> progenitor exhausted CD8 <sup>+</sup> T cells in Acute Myeloid LeukemiaSemantic proximity Read ↗

High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.